HeartBeam Launches Pilot Study of On-Demand 12-Lead ECG Patch for Ischemia Detection

HeartBeam (NASDAQ: BEAT) announced the launch of a pilot study focused on testing its proprietary patch capable of generating on-demand 12-lead ECGs for detecting coronary artery disease and ischemia. The study marks a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.

Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam's technology aims to fill a critical gap in ambulatory monitoring.

“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could transform how physicians monitor patients for silent ischemia and coronary artery disease outside of clinical settings.”

The pilot study will evaluate the patch's ability to capture high-quality ECG signals comparable to traditional 12-lead ECGs, which are the gold standard for diagnosing myocardial ischemia. Current patch-based monitors typically offer fewer leads or lower fidelity, limiting their diagnostic utility. If successful, HeartBeam's patch could enable continuous, long-term monitoring with on-demand acquisition of clinical-grade ECGs, allowing for early detection of ischemic events that might otherwise go unnoticed.

The implications of this study extend beyond product development. For patients with known or suspected coronary artery disease, the ability to generate a 12-lead ECG on demand at home could reduce the need for frequent clinic visits and emergency room trips. For healthcare systems, earlier detection of ischemia could lead to better outcomes and lower costs associated with advanced cardiovascular disease. The study also positions HeartBeam to compete directly with established players in the cardiac monitoring space, offering a unique value proposition of diagnostic-quality ECGs from a wearable patch.

HeartBeam's technology has already garnered attention from investors and industry observers. The company's newsroom provides updates and further details on the study and its progress. Interested parties can view the original press release for more information.

Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's filings with the SEC. The company undertakes no duty to update this information unless required by law.